Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real‐world: Results from the <scp>SCORE</scp> study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World)
In this real-world study of US individuals with ASCVD and overweight/obesity but without diabetes, semaglutide 2.4 mg was associated with significantly reduced risk of MACEs and other obesity-related morbidities (NCT06874751).
Authors
- B. Gabriel Smolarz (ORCID: https://orcid.org/0000-0002-8591-3858)
- Zhenxiang Zhao (ORCID: https://orcid.org/0000-0002-6804-1111)
- Kim G. Smolderen (ORCID: https://orcid.org/0000-0001-6104-6254)
- Michael G. Nanna (ORCID: https://orcid.org/0000-0001-5745-1636)
- Carlos Mena‐Hurtado (ORCID: https://orcid.org/0000-0002-4954-5672)
- Mikhail Kosiborod (ORCID: https://orcid.org/0000-0002-3750-9789)
- Mads Faurby (ORCID: https://orcid.org/0000-0001-6464-9958)
- Yan Chen (ORCID: https://orcid.org/0000-0002-5317-1909)
- Wojciech Michalak
- James P. Boland
- Jinlin Song
Institutions
- Yale University (US)
- Novo Nordisk (United States) (US)
- University of Missouri–Kansas City (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1111/dom.70080
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Novo Nordisk